Hypericum extract in patients with MDD and reversed vegetative signs: Re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo

International Journal of Neuropsychopharmacology

Volumn 8, Issue 2, 2005, Pages 215-221

  Murck, Harald ^a,e   Fava, Maurizio ^b   Alpert, Jonathan ^b   Nierenberg, Andrew A ^b   Mischoulon, David ^b   Otto, Michael W ^b   Zajecka, John ^c   Mannel, Marcus ^d   Rosenbaum, Jerrold F ^b  

^a Lichtwer Pharma GmbH   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Ad libitum Medical Services   (Germany)

^e Laxdale Ltd   (United Kingdom)

Author keywords

Atypical depression; Major depression; Reversed vegetative signs; St. John's wort

Indexed keywords

FLUOXETINE; HYPERICUM EXTRACT; PLACEBO;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HUMAN; HYPERPHAGIA; HYPERSOMNIA; MAJOR DEPRESSION; MALE; MELANCHOLIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSED VEGETATIVE SIGNS; SAMPLE SIZE; STATISTICAL ANALYSIS;

ANALYSIS OF VARIANCE; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FLUOXETINE; HUMANS; HYPERICUM; PHYTOTHERAPY; PLACEBOS; PLANT EXTRACTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME;

EID: 20044371495     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004717     Document Type: Article

References (35)

1. Antonijevic IA, Murck H, Frieboes RM, Steiger A (2000). Sexually dimorphic effects of GHRH on sleep-endocrine activity in patients with depression and normal controls. Part II: Hormone secretion. Sleep Research Online 3, 15-21.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: American Psychiatric Association.
3. Breslau N, Roth T, Rosenthal L, Andreski P (1996). sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biological Psychiatry 39, 411-418.
4. Casper RC, Kocsis J, Dysken M, Stokes P, Croughan J, Maas J (1988). Cortisol measures in primary major depressive disorder with hypersomnia or appetite increase. Journal of Affective Disorders 15, 131-140.
5. Casper RC, Swann AC, Stokes PE, Chang S, Katz MM, Garver D (1987). Weight loss, cortisol levels, and dexamethasone suppression in major depressive disorder. Acta Psychiatrica Scandinavica 75, 243-250.
6. Cohen J (1977). Statistical Power Analysis for the Behavioral Sciences (rev. edn). New York: Academic Press.
7. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF (2002). Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. Journal of Clinical Psychopharmacology 22, 379-387.
8. Fava M, Alpert JE, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF (In Press). Journal of Clinical Psychopharmacology.
9. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM (1994). Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. American Journal of Psychiatry 151, 1372-1374.
10. Gold PW, Chrousos GP (1998). The endocrinology of melancholic and atypical depression: relation to neurocircuity and somatic consequences. Proceedings of the Association of American Physicians 111, 22-34.
11. Halama P (1991). Wirksamkeit Des Hypericum-Extraktes LI 160 Bei 50 Patienten Einer Psychiatrischen Fachpraxis. Nervenheilkunde 10, 305-307.
12. Holsboer-Trachsler E, Brand S, Hatzinger M, Hemmeter U (2001). Effects of hypericum extract on sleep-EEC and DEX/CRH-test in patients with depression. Biological Psychiatry 49, 9S.
13. Hübner W-D, Lande S, Podzuweit H (1994). Hypericum treatment of mild depressions with somatic symptoms. Journal of Geriatric Psychiatry and Neurology 7, 12-14.
14. Hypericum Depression Trial Study Group (2002). Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: a randomized controlled trial. Journal of the American Medical Association 287, 1807-1814.
15. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM, Stevens IF (2002). Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Australian and New Zealand Journal of Psychiatry 36, 384-391.
16. Kasper S (1997). Treatment of seasonal affective disorder (SAD) with hypericum extract. Pharmacopsychiatry 30 (Suppl. 2), 89-93.
17. Kirsch I, Moore TJ, Scoboria A, Nicholls SS (2002). The emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. food and drug administration. Prevention and Treatment 5, 1-10.
18. Kupfer DJ, Frank E (2002). Placebo in clinical trials for depression - complexity and necessity. Journal of the American Medical Association 287, 1853-1854.
19. Lecrubier Y, Clerc G, Didi R, Kieser M (2002). Efficacy of St. John's Wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. American Journal of Psychiatry 159, 1361-1366.
20. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O (1994). Moclobemide and fluoxetine in atypical depression: a double-blind trial. Journal of Affective Disorders 32, 169-177.
21. Martinez B, Kasper S, Ruhrmann S, Möller H-J (1994). Hypericum in the treatment of seasonal affective disorders. Journal of Geriatric Psychiatry and Neurology 7, 29-33.
22. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF (2000a). A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. American Journal of Psychiatry 157, 344-350.
23. McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF, Beasley CMJ (2000b). Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. Journal of Clinical Psychiatry 61, 518-524.
24. Murck H (2003). Atypical depression spectrum disorder - neurobiology and treatment. Acta Neuropsychiatrica 15, 227-41.
25. Nickel T, Sonntag A, Schill J, Zobel AW, Ackl N, Brunnauer A, Murck H, Ising M, Yassouridis A, Steiger A, Zihl J, Holsboer F (2003). Clinical and neurobiological effects of tianeptine and paroxetine in major depression. Journal of Clinical Psychopharmacology 23, 155-168.
26. Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M (1998). Course and treatment of atypical depression. Journal of Clinical Psychiatry 59 (Suppl. 18), 5-9.
27. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF (1996). Fluoxetine versus phenelzine in atypical depression. Biological Psychiatry 40, 1017-1020.
28. Parker G (2001). 'New' and Old' antidepressants: all equal in the eyes of the lore? British Journal of Psychiatry 179, 95-96.
29. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U (2001). Effectiveness of St John's Wort in major depression - a randomized controlled trial. Journal of the American Medical Association 285, 1978-1986.
30. Sogaard J, Lane R, Latimer P, Behnke K, Christiansen PE, Nielsen B, Ravindran AV, Reesal RT, Goodwin DP (1999). A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. Journal of Psychopharmacology 13, 406-414.
31. Sommer H, Harrer G (1994). Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients. Journal of Geriatric Psychiatry and Neurology 7, S9-S11.
32. Sotsky SM, Simmens SJ (1999). Pharmacotherapy response and diagnostic validity in atypical depression. Journal of Affective Disorders 54, 237-247.
33. Volz H-P, Murck H, Kasper S, Möller H-J (2002). St. John's Wort extract (LI 160) in somatoform disorders - results of a placebo-controlled trial. Psychopharmacology 164, 294-300.
34. Wheatley D (1999). Hypericum in seasonal affective disorder (SAD). Current Medical Research and Opinion 15, 33-37.
35. Woelk H, Burkard G, Grünwald J (1994). Benefits and risks of the hypericum extract LI160 drug monitoring study with 3250 patients. Journal of Geriatric Psychiatry and Neurology 7, 34-38.